The Realities of Running Next-Generation Sequencing Liquid Biopsy Panels in Clinical Trials
In this talk, Almac Diagnostic Services VP of UK Operations, Dr Leeona Galligan, will explore the realities of running next-generation sequencing (NGS) liquid biopsy panels in biomarker-driven clinical trials from a CLIA laboratory diagnostic provider viewpoint.
We will discuss the opportunities and challenges of NGS liquid biopsy panels and the critical steps involved in ensuring that they are ready for stratification use within clinical trials, as demonstrated by a biotech case study.
Almac Diagnostic Services has experience in both the development & analytical validation of blood-based molecular biomarkers so that the assays are both robust and compliant with appropriate global regulatory frameworks for prospective clinical trial stratification.
What You Will Learn
- Key aspects of running NGS liquid biopsy panels in biomarker-driven clinical trials
- Challenges of demonstrating adequate analytical performance of the panel
- The importance of adequate specimen collection and stabilisation
- Data analysis pipeline considerations for liquid biopsy panels
Your global partner for biomarker discovery, development & commercialisation.
We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.
Clinical Trial Assays
Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.
A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.